Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 57 points (0.3%) at 16,611 as of Monday, Aug. 11, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 2,452 issues advancing vs. 535 declining with 124 unchanged. The Health Care sector currently sits up 1.1% versus the S&P 500, which is up 0.6%. Top gainers within the sector include Alnylam Pharmaceuticals ( ALNY), up 3.5%, ResMed ( RMD), up 2.3%, Incyte ( INCY), up 2.1%, Smith & Nephew ( SNN), up 2.1% and Pharmacyclics ( PCYC), up 1.9%. On the negative front, top decliners within the sector include Allergan ( AGN), down 2.2%, Illumina ( ILMN), down 2.1%, HCA Holdings ( HCA), down 1.0%, Aetna ( AET), down 0.9% and Mylan ( MYL), down 0.8%. TheStreet would like to highlight 3 stocks pushing the sector higher today: 3. Eli Lilly and ( LLY) is one of the companies pushing the Health Care sector higher today. As of noon trading, Eli Lilly and is up $0.46 (0.8%) to $61.44 on light volume. Thus far, 1.4 million shares of Eli Lilly and exchanged hands as compared to its average daily volume of 4.0 million shares. The stock has ranged in price between $61.10-$61.87 after having opened the day at $61.35 as compared to the previous trading day's close of $60.98. Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health Products. Eli Lilly and has a market cap of $67.4 billion and is part of the drugs industry. Shares are up 18.3% year-to-date as of the close of trading on Friday. Currently there are 5 analysts who rate Eli Lilly and a buy, 1 analyst rates it a sell, and 8 rate it a hold. TheStreet Ratings rates Eli Lilly and as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Eli Lilly and Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.